Group 1 - Shenzhen Metro has introduced a delivery robot that autonomously navigates the subway system to deliver goods to convenience stores, marking a global first in robot-assisted logistics within public transport [1][4] - On July 11, Shenzhen Metro recorded a passenger volume of 10.47 million, indicating strong growth with 24 days this year surpassing 10 million passengers [3] - The integration of delivery robots aims to solve logistical challenges faced by subway shops, such as high costs and parking difficulties associated with ground transportation [4][6] Group 2 - The delivery robot utilizes advanced technologies including AI scheduling algorithms and panoramic laser radar for navigation and operational efficiency [6] - The collaboration between Shenzhen Metro and Vanke Logistics represents a strategic move towards technology-driven logistics solutions, enhancing service efficiency for subway merchants [6][7] - Shenzhen's initiative aligns with its goal to become a testing ground for new technologies, as outlined in the city's action plan for intelligent robotics development from 2025 to 2027 [7]

近日，英飞特电子与浙江东江绿色石化技术创新中心有限公司正式签署战略合作框架协议，双方将携手 在绿色低碳领域展开深度协同，共同探索石油化工行业节能降耗的创新路径，助力产业绿色转型升级。 强强联手，共筑绿色未来 此次合作不仅是两家企业的技术融合，更是对行业绿色发展的积极回应。双方将建立长期、稳定的合作 机制，推动节能降碳技术的规模化落地，为行业提供可复制、可推广的低碳范例。 浙江东江绿色石化技术创新中心有限公司由浙江荣盛控股集团有限公司、浙江瑞盛科技创新有限公司、 浙江石油化工有限公司、浙江大学、浙江永盛科技有限公司、天津大学浙江研究院和浙江逸盛新材料有 限公司共同出资成立。创新中心围绕绿色石油化工新工艺，重点攻关节能降碳绿色石化技术、固体废弃 物减量化资源化利用两大方向以及化工新材料、工业智能应用等。英飞特电子是全球领先的照明系统解 决方案提供商，凭借先进电力电子技术和智能制造技术等优势，为全球客户提供高效、可靠的节能产 品。 在全球"双碳"目标下，绿色技术已成为产业竞争的新赛道。东江绿色石化技术创新中心董事长杨生东表 示："此次合作是'产学研用'深度融合的典范，我们将以创新为纽带，推动石化行业绿色转型。" 英 ...

签约后，双方将从建设一流的战略合作供应链的高度，建立即时信息共享机制，深化沟通渠道，定期开 展技术交流；共同打造行业领先的工艺和质量水准；双方将在联合品牌推广、智能悬架系统研发、智能 辅助驾驶技术创新、各类传感器研发等新技术应用、关键技术及零部件供应链安全等各方面建立广泛深 入的合作平台，共同制定行动方案，共建战略联盟。 保隆科技将持续投入，聚焦智能悬架、TPMS、传感器、智能辅助驾驶等关键技术，与江淮汽车的技术 团队形成研发联动，确保精准对接江淮汽车的需求；在技术创新上，同步分享保隆科技在智能化、轻量 化领域的最新成果，助力江淮汽车车型持续领跑行业；在供应链安全上，将合肥基地的产能优先保障江 淮汽车的需求，实现关键零部件本地化生产和供应；在成本优化上，通过VAVE降本合作，与江淮汽车 共同打造更具市场竞争力的产品，让更多人受益于汽车科技的发展！ 7月24日上午，在江淮汽车合肥总部，保隆科技与江淮汽车签订战略合作协议。江汽集团控股公司党委 书记、董事长、总经理项兴初，江汽集团控股公司董事、江汽集团股份有限公司副总经理马翠兵，采购 中心总经理秦战江、技术中心底盘设计院院长吴江等领导，保隆科技董事长兼总裁张祖秋、 ...

欧伦电气作为全品类除湿机领域的领先企业，在技术创新、产品创新、生产创新和标准创新方面均取得 显著成果。在技术创新上，公司凭借多年积累，掌握了风轮优化、节能热回收、双向导风、低温除湿等 核心技术，并拥有330项专利和23项软件著作权，确保设备在质量和技术上的行业领先地位。产品创新 方面，公司紧跟市场需求，不仅提供常规除湿机、移动空调等设备，还能定制耐腐蚀、防爆等特种产 品，同时自主研发的空气源热泵和车载冰箱已进入市场放量阶段，增强了盈利能力。生产创新上，公司 通过引进先进设备、优化工艺和管理手段，提升效率并降低成本，同时建设焓差实验室和噪音实验室， 保障产品质量和研发能力。标准创新方面，公司参与制定多项行业及团体标准，并作为第一起草单位主 导新版《除湿机》国家标准（GB/T19411-2024）的修订，进一步巩固了行业话语权。 在生产制造方面，欧伦电气已建成14万平方米的智能化生产基地，另有11万平方米的新基地正在建设 中。这些现代化生产基地配备了先进的自动化生产设备和信息化管理系统，通过立体化包装流水线、机 器人码垛机等智能化设备，大幅提升了生产效率，降低了人工成本。公司建立了严格的质量管控体系， 先后通过I ...

Core Viewpoint - Huadong Medicine's subsidiary has received approval for the Phase III clinical trial of MC2-01 cream for treating plaque psoriasis, marking a significant step towards clinical application and enhancing the company's portfolio in dermatological formulations [1][2][3] Group 1: Product Development and Market Potential - MC2-01 cream is a fixed-dose combination of calcipotriene and betamethasone, designed for the topical treatment of adult plaque psoriasis, including scalp psoriasis [2][3] - The Chinese psoriasis treatment market is rapidly growing, with projections estimating it will reach USD 3.25 billion by 2025 and further increase to USD 9.94 billion by 2030 [2] - Approximately 80%-90% of psoriasis patients globally have the plaque type, indicating a significant demand for effective treatment options in China, where the number of plaque psoriasis patients is expected to reach 6.168 million by 2030 [3] Group 2: Competitive Advantage and Product Pipeline - Huadong Medicine has established a comprehensive pipeline in the autoimmune field, with over 20 innovative products in development, covering various conditions including psoriasis, atopic dermatitis, and more [4] - The company has created a "golden product combination" in psoriasis treatment, including monoclonal antibodies, oral medications, and topical formulations, aiming to provide a wide range of options for patients [5][6] - The company is actively pursuing collaborations and has received approvals for multiple products, enhancing its competitive position in the dermatological market [6] Group 3: Strategic Vision and Future Outlook - Huadong Medicine aims to become a globally influential innovative pharmaceutical company, focusing on accelerating strategic layouts across multiple fields and delivering breakthrough treatment solutions for patients [7]

东方财富证券投资者教育基地于2025年7月21日携手全球领先的人工智能与人形机器人企业——深圳市 优必选科技股份有限公司（以下简称"优必选"），组织开展了"走进优必选，领航机器人时代"调研交流 活动，此次活动由东方财富证券深圳科技园证券营业部承办，通过企业展厅参观、智能机器人互动体验 及高管深度交流，让投资者近距离感受智能机器人的技术魅力，深入了解优必选的商业化布局及未来发 展前景。 在互动体验区，投资者们亲身感受了人形机器人的科技魅力。优必选人形机器人展示了多项交互功能： 投资者与人形机器人亲切握手，人形机器人精准识别指令并完成物品拿取任务，还现场表演了一段流畅 的太极拳，其灵活的动作和快速的反应能力让在场观众赞叹不已。最受欢迎的环节是投资者亲自向人形 机器人发出指令，通过语音交互，人形机器人能够准确理解并执行各种任务，展示了强大的识别和处理 能力。一位参与体验的投资者表示："人形机器人的反应速度和执行精度超出预期，这种亲身体验比看 资料更直观地感受到优必选的技术实力。" 图片1.png 走进优必选：领略智能科技发展新成果 在优必选讲解员的引导下，投资者首先参观了公司展厅，系统了解了企业的发展历程和技术实力 ...

Group 1 - The core viewpoint of the news is that Zhejiang Zhongde Automation Technology Co., Ltd. (Zhongde Technology) has entered the IPO inquiry stage, aiming to raise 190 million yuan through the issuance of up to 22.15 million shares [1] - The funds raised will be allocated to various projects, including 80 million yuan for intelligent actuator construction, 79.5 million yuan for control valve technology upgrades and capacity enhancement, and 30 million yuan for working capital [1] - Zhongde Technology specializes in the research, production, and sales of industrial control valves and automation control systems, with products widely used in industries such as petrochemicals, natural gas, and coal chemicals [1][2] Group 2 - The company has been recognized as a national key specialized and innovative "little giant" enterprise, establishing a significant competitive advantage in the petrochemical control valve sector through technological innovation and high product quality [1][2] - Zhongde Technology has developed multiple core technologies, including high-temperature wear-resistant technology and ultra-low temperature sealing technology, enabling its products to operate under extreme conditions [2] - As of the signing date of the prospectus, the company and its subsidiaries hold 123 patents, including 40 invention patents, and have participated in the formulation of 12 national standards and 1 industry standard [2] Group 3 - Zhongde Technology has established a comprehensive quality control system in its manufacturing process, utilizing advanced inspection and testing equipment to ensure product quality [3] - The company has obtained various certifications, including ISO quality management and environmental management system certifications, as well as international certifications such as API-6D and API-600 [3] - The company has successfully entered the supply chain of major petrochemical enterprises like Sinopec and CNOOC, maintaining qualified supplier status for over a decade [3] Group 4 - The company has a deep understanding of customer needs in the petrochemical industry, allowing it to provide customized solutions and professional selection advice [4] - Located in the core area of the Yangtze River Delta, Zhongde Technology benefits from a well-developed industrial support system, abundant talent resources, and efficient logistics networks [4] Group 5 - The Zhejiang provincial government has identified high-end control valves as a key development area during the 14th Five-Year Plan, providing supportive policies that Zhongde Technology is leveraging to enhance its R&D efforts [5] - The company has established a nationwide marketing service network, employing a direct sales model with well-trained personnel to ensure timely responses to customer needs [5] - Zhongde Technology's service system covers the entire process from pre-sales to after-sales, significantly enhancing customer satisfaction and market reputation [5] Group 6 - The demand for high-performance control valves in the petrochemical industry is expected to continue growing against the backdrop of carbon neutrality goals and industrial upgrades, positioning Zhongde Technology for further development [6]

Core Viewpoint - The collaboration between Giant Star Legend and Yushu Technology aims to develop and commercialize consumer-grade robots with strong IP attributes, focusing on four-legged robotic dogs that have companionship and social interaction features [1][2]. Group 1: Collaboration Details - The partnership will leverage both companies' strengths, with Giant Star Legend focusing on IP planning and AI interaction design, while Yushu Technology will handle hardware development [2][3]. - The collaboration is not merely about IP licensing but aims to create robots that embody emotional resonance through storytelling and character design, enhancing user connection [2][3]. - The robots will be utilized in various scenarios, including concerts and performances, to extend the influence of IP and unlock commercial potential [3][6]. Group 2: Financial Planning and Investment - Giant Star Legend plans to allocate approximately 38.2% (around 124 million HKD) of the funds raised from a recent share placement to expand its retail network, including vending machines and smart mechanical devices [3][4]. - The total amount raised from the share placement is approximately 342.6 million HKD, with a net amount of about 324 million HKD after deducting issuance costs [4]. Group 3: Market Insights - The consumer-grade robot market has significant potential, but the willingness of domestic users to pay for "IP + robots" has yet to be fully validated [5]. - Experts suggest that the development of humanoid robots should initially focus on high-visibility public entertainment scenarios, following a path from entertainment to industrial applications and finally to household use [5].

Core Viewpoint - The announcement by the National Medical Products Administration regarding the optimization of clinical trial review and approval for innovative drugs is a significant positive development for the industry, particularly as it reduces the review time from 60 to 30 working days for innovative drug applications, including traditional Chinese medicine (TCM) [1] Group 1: Industry Overview - The recognition of TCM as an essential part of innovative drugs contrasts with the capital market's perception, which has not seen significant growth in TCM companies despite a surge in innovative drug stocks this year [1] - The modernization of TCM is gaining traction, supported by national policies, emphasizing the integration of traditional advantages with modern scientific techniques [3][4] Group 2: Company Profile - Yiling Pharmaceutical - Yiling Pharmaceutical is a leading innovative drug company with a focus on TCM, biopharmaceuticals, and health products, with TCM being the primary revenue and profit contributor [1] - As of the end of 2024, Yiling Pharmaceutical holds 17 patented TCM products covering eight major clinical disease systems, leading in the cardiovascular and respiratory disease treatment sectors [1] Group 3: Financial Performance - In 2024, Yiling Pharmaceutical's revenue from cardiovascular drugs exceeded 3.8 billion, while respiratory drugs accounted for less than 800 million, together representing over 70% of total revenue [9] - The company has experienced a decline in revenue over the past two years, primarily due to a significant drop in demand for its product Lianhua Qingwen post-pandemic [11] Group 4: Research and Development - Yiling Pharmaceutical has consistently ranked among the top in R&D investment within the A-share TCM sector, with annual R&D expenditures of approximately 895 million, 935 million, and 908 million over the past three years, representing 7.15%, 9.06%, and 13.94% of revenue respectively [5] - The company has achieved notable academic breakthroughs, including a landmark study published in a top medical journal demonstrating the efficacy of its product Tongxinluo in reducing cardiovascular events [6] Group 5: Growth Potential - Yiling Pharmaceutical's core competitive advantage lies in its founder's innovative theory on vascular diseases, which has attracted international research interest [12] - The company has five new drugs approved in the past five years, with four included in the medical insurance directory, indicating a strong pipeline for future growth [12] - The current market valuation of Yiling Pharmaceutical is estimated to be around 300 billion, with potential for significant appreciation as the market begins to recognize the value of innovative TCM [16]

7月29日，2025世界斯诺克·上海大师赛的星光，"意外"照亮了"放心家园·安心暑托班"的课堂！斯诺克大 师约翰·希金斯化身"孩子王"，惊喜现身上海银行"童享美好"专项基金支持的安心暑托班，为孩子们带 来一场充满欢笑与惊喜的"小球大梦想"互动盛宴。 4.jpg 快乐碰撞，小球迸发大梦想 Mini台球、康乐球、乒乓球……在上海台球协会裁判长张迺俊一场生动活泼的科普课后，小小的暑托班 教室化身为充满活力的"童趣赛场"。约翰·希金斯也化身"全能教练"，兴致勃勃地与孩子们"切磋"起各类 球艺。 "Very good ，你们真的很棒！" 握杆、瞄准、发力……约翰·希金斯耐心地指导着小朋友，看着小球在孩子们稚嫩却认真的击打下应声 入袋，他毫不吝啬地送上掌声和鼓励。 "希金斯叔叔，世界冠军是怎么炼成的呀？" 面对孩子们的提问，约翰·希金斯深情的分享道，"需要持之以恒、勤于练习。斯诺克不仅是竞技，更蕴 含着专注、策略和永不言弃的精神。它拥有改变人生、改变世界的力量。" 一位全程参与的家长也感慨道："这场互动让孩子们在'玩'中感受到运动的快乐和追求卓越的可能。希 金斯的分享也将成为孩子们受用一生的'精神食粮'" 孩子们的健康成 ...